This is a working overview of albumin conjugate, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
is the spatial velocity gradient tensor. If only these two original criteria are used to define hypoelasticity, then hyperelasticity would be included as a special case, which prompts some constitutive modelers to append a third criterion that specifically requires a hypoelastic model to not be hyperelastic (i.e., hypoelasticity implies that stress is not derivable from an energy potential). If this third criterion is adopted, it follows that a hypoelastic material might admit nonconservative adiabatic loading paths that start and end with the same deformation gradient but do not start and end at the same internal energy. Note that the second criterion requires only that the function
=== Negative feedback === Calcitriol helps regulate vitamin D levels through a negative feedback mechanism. It strongly upregulates the expression of the enzyme CYP24A1, which inactivates vitamin D. This activation happens through binding of the activated vitamin D receptor (VDR) to two vitamin D response elements (VDREs) in the CYP24A1 gene. VDR also recruits proteins like histone acetyltransferases and RNA polymerase II to enhance this process. At the same time, calcitriol suppresses the production of CYP27B1, another enzyme involved in vitamin D metabolism, by modifying its gene's promoter region through an epigenetic mechanism. Together, these actions help tightly control vitamin D levels in the kidney.
There are two dedicated Noma hospitals in Nigeria, the first and oldest of which is the Noma Children Hospital Sokoto, staffed by resident and visiting medical teams supported by Médecins Sans Frontières. Some of the staff are noma survivors. The second and more recently commissioned centre is the Noma Centre Abuja, fully funded and sponsored by the Noma Aid Nigeria Initiative, where holistic and compressive management of the Noma patients is given. The team consists of a resident medical and surgical team and visiting surgeons from Europe. In other countries, such as Ethiopia, international charities work in collaboration with the local health care system to provide complex reconstructive surgery which can give back facial functions such as eating, speaking, and smiling. Teams of volunteer medics coming from abroad are often needed to support the local capacity to address the most severe cases, which can be extremely challenging even for senior maxillofacial surgeons. On 10 June 2010, the work of such volunteer surgeons was featured in a UK BBC Two documentary presented by Ben Fogle, Make Me a New Face: Hope for Africa's Hidden Children.
=== Oxygen and atmosphere control === Oxygen scavengers, also called oxygen absorbers, remove residual oxygen from a sealed package. Reducing oxygen can slow lipid oxidation, colour changes, vitamin degradation, mould growth, and the growth of aerobic spoilage organisms. Iron-based oxygen absorbers commonly contain iron powder and supporting ingredients that allow oxidation to occur. Other systems use ascorbic acid, enzymes, unsaturated organic compounds, microorganisms, antioxidants, or oxygen-scavenging polymers. The active material may be supplied in a sachet, card, label, bottle closure, tray, film, liner, or moulded package component. Sachets must be clearly identified and protected against accidental opening or ingestion. In practical dry-food storage, oxygen-absorber sachets may be placed inside suitable high-barrier Mylar pouches before heat sealing. The food type, moisture level, absorber capacity, seal integrity, and package barrier must be appropriate for reduced-oxygen storage. The effectiveness of an oxygen scavenger is partly determined by the package's oxygen transmission rate. A low-transmission barrier limits the amount of oxygen entering after the initial oxygen has been removed. A high-barrier film remains passive packaging when used without an active component. Modified atmosphere packaging changes the concentration of gases surrounding a product. Nitrogen, carbon dioxide, oxygen, or mixtures of these gases may be selected according to the product and its spoilage mechanisms.
By 2015, the average fiber content per pack of MRE has improved to an adequate 12 grams. A superstition exists among troops about the Charms candies that come with some menus: they are considered bad luck, especially if actually eaten. In March 2007, The Salt Lake Tribune invited three gourmet chefs to taste-test 18 MRE meals. None of the meals rated higher than a 5.7 average on a scale of 1 to 10, and the chicken fajita meal in particular was singled out for disdain, rating an average score of 1.3. In 2010, the New York Times reported that a French combat ration (such as cassoulet with accompaniments of deer pâté and nougat) could be traded for around five MREs, though by 2014 it was claimed that MRE menus had improved to the point that their worth had reversed. The vegetable cheese omelet MRE, Recipe No. 4, introduced in 2005, is generally considered the worst ever. Soldiers serving in Iraq dubbed it the "Vomelet" (a pun with vomit), both for its appearance and taste. It was discontinued in 2009.
Sources: en.wikipedia.org
DszA is responsible for the third step of the pathway. It catalyzes the first carbon-sulfur bond cleavage, converting DBT-sulfone into 2-hydroxybiphenyl-2-sulfinate. Like DszC, DszA also requires FMNH2 provided by DszD and molecular oxygen for its catalytic cycle. Nonetheless, the reaction rate of DszA is about seven times faster than DszC. However, like DszC, it suffers feedback inhibition by the final product of the pathway, 2-HBP. At last, the desulfinase (DszB) cleaves the remaining carbon-sulfur bond in 2-hydroxybiphenyl-2-sulfinate converting it into the sulfur-free 2-hydroxybiphenyl in a two step mechanism. In the first, and rate-limiting, step, 2-hydroxybiphenyl-2-sulfinate is protonated by Cys27 in its electrophilic carbon leading to the cleavage of the carbon-sulfur bond and displacement of SO2. In the second step, a water molecule is deprotonated by Cys27 followed by the hydroxide attack to SO2 forming HSO3−. DszB is the least efficient enzyme on the pathway making it an appealing target for enhancement through protein engineering. The NADH-FMN oxidoreductase (DszD) regenerates the FMNH2 cofactor needed for the reactions catalyzed by DszC and DszA, through the oxidation of NADH to NAD+ in a two step mechanism. The first step corresponds to a hydride transfer from the nicotinamide moiety of NADH to the central nitrogen in the isoalloxazine moiety of the oxidized FMN forming FMNH. In the second step, a water molecule protonates the N1 atom of FMNH giving FMNH2.
=== Angle restraints === In addition to distance restraints, restraints on the torsion angles of the chemical bonds, typically the psi and phi angles, can be generated. One approach is to use the Karplus equation, to generate angle restraints from coupling constants. Another approach uses the chemical shifts to generate angle restraints. Both methods use the fact that the geometry around the alpha carbon affects the coupling constants and chemical shifts, so given the coupling constants or the chemical shifts, a qualified guess can be made about the torsion angles.
== Environmental issues == Light pollution: Because white LEDs emit more short wavelength light than sources such as high-pressure sodium vapor lamps, the increased blue and green sensitivity of scotopic vision means that white LEDs used in outdoor lighting cause substantially more sky glow. Impact on wildlife: LEDs are much more attractive to insects than sodium-vapor lights, so much so that there has been speculative concern about the possibility of disruption to food webs. LED lighting near beaches, particularly intense blue and white colors, can disorient turtle hatchlings and make them wander inland instead. The use of "turtle-safe lighting" LEDs that emit only at narrow portions of the visible spectrum is encouraged by conservancy groups in order to reduce harm. Use in winter conditions: Since they do not give off much heat in comparison to incandescent lights, LED lights used for traffic control can have snow obscuring them, leading to accidents.
In protein sequencing, aminopeptidases are employed in the Edman degradation method. This technique involves the sequential removal and identification of the N-terminal amino acid of proteins, facilitating the elucidation of their amino acid sequence.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.